Compare NTRB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRB | LSTA |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Industrial Specialties | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | NTRB | LSTA |
|---|---|---|
| Price | $3.06 | $3.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 9.7K | ★ 95.2K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $2.90 | $1.81 |
| 52 Week High | $11.68 | $5.07 |
| Indicator | NTRB | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 45.00 |
| Support Level | $2.90 | $3.06 |
| Resistance Level | $3.67 | $3.41 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 14.58 | 2.86 |
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.